Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIOZ29)

• Drug Name: Glycine Drug Info
• Synonyms: Aciport; Aminoazijnzuur; Aminoessigsaeure; Amitone; Corilin; Glicina; Glicoamin; Gly; Glycin; Glycinum; Glycocoll; Glycolixir; Glycosthene; Glykokoll; Glyzin; Hgly; Leimzucker; Padil; Polyglycine; Acide aminoacetique; Acido aminoacetico; Acidum aminoaceticum; Aminoacetic acid; Aminoethanoic acid; An alpha amino acid ester; Glycine [INN]; Hampshire glycine; Polyglycine II; Sucre de gelatine; Acide aminoacetique [INN-French]; Acido aminoacetico [INN-Spanish]; Acidum aminoaceticum [INN-Latin]; GLY (IUPAC abbrev); GLYCINE, ACS; Glicina [INN-Spanish]; Glycinum [INN-Latin]; Gyn-hydralin; L-Glycine; S04-0135; AB-131/40217813; AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER; GLYCINE 1.5% IN PLASTIC CONTAINER; Glycine (JP15/USP); Glycine iron sulphate (1:1); Glycine, homopolymer (VAN); Glycine, labeled with carbon-14; Glycine, non-medical; Glycine-UL-14C hydrochloride; H-Gly-OH; H2N-CH2-COOH; L-alpha-amino acids; (1-13c)glycinato; (15N)Glycine; 2,2-dialkylglycines; 2-Aminoacetic acid

Indication

Disease Entry	ICD 11	Status	REF
Malnutrition	5B50-5B71	Approved	[1] , [2]

• Therapeutic Class: Dietary supplement
• Cross-matching ID:
  PubChem CID: 750
  ChEBI ID: CHEBI:15428
  CAS Number: CAS 56-40-6
  TTD Drug ID: DMIOZ29
  VARIDT Drug ID: DR00242
  INTEDE Drug ID: DR2025

Molecule-Related Drug Atlas

Drug(s) Metabolized By Bile acid-CoA thioesterase (BAAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[12]
Taurine	DMVW7N3	Discovery agent	N.A.	Investigative	[10]
ZX-AP000068	DM4Y0NI	Discovery agent	N.A.	Investigative	[10]
NSC-39851	DMMXZBK	Discovery agent	N.A.	Investigative	[10]

Drug(s) Transported By Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aciclovir	DMYLOVR	Virus infection	1A24-1D9Z	Approved	[13]
Ganciclovir	DM1MBYQ	Virus infection	1A24-1D9Z	Approved	[13]
Levacecarnine HCL	DMJBOCR	Cognitive impairment	6D71	Approved	[14]
L-glutamine	DM69G8X	Short bowel syndrome	KB89.1	Approved	[15]
Valaciclovir	DMHKS94	Virus infection	1A24-1D9Z	Approved	[16]
Valganciclovir	DMS2IUH	Virus infection	1A24-1D9Z	Approved	[17]
Nitric Oxide	DM1RBYG	Respiratory failure	CB41	Approved	[18]
D-Serine	DM3YH4I	N. A.	N. A.	Phase 4	[19]
L-threonine	DMFHTBX	Discovery agent	N.A.	Investigative	[19]

Drug(s) Transported By Proton-coupled amino acid transporter 1 (SLC36A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Proline	DMKSTWR	Malnutrition	5B50-5B71	Approved	[20]
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[21]
Aminolevulinic acid hci	DMS4BLQ	Acne vulgaris	ED80	Approved	[22]
Gaboxadol	DMI53FU	Insomnia	7A00-7A0Z	Approved	[23]
Vigabatrin	DMYT0OG	Complex partial seizure	8A68.0	Approved	[24]

Drug(s) Transported By Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[25]
L-Proline	DMKSTWR	Malnutrition	5B50-5B71	Approved	[6]
Betaine	DMGRZW2	Inborn error of metabolism	5C50-5C59	Approved	[26]
Choline	DM5D9YK	Discovery agent	N.A.	Investigative	[6]

Drug(s) Transported By Sodium- and chloride-dependent glycine transporter 2 (SLC6A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Norepinephrine	DMOUC09	Sepsis	1G40-1G41	Approved	[27]
Methylphenidate	DM7SJD6	Attention deficit hyperactivity disorder	6A05.Z	Approved	[28]

Drug(s) Transported By Sodium- and chloride-dependent glycine transporter 1 (SLC6A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sarcosine	DMIVGOR	Discovery agent	N.A.	Investigative	[29]

Drug(s) Transported By L-type amino acid transporter 2 (SLC7A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[7]
L-alanine	DMZDN4W	Dietary shortage	5B5K	Approved	[7]
L-Proline	DMKSTWR	Malnutrition	5B50-5B71	Approved	[7]
L-Phenylalanine	DMQXI9F	Malnutrition	5B50-5B71	Approved	[30]
L-tyrosine	DM9O8DT	Malnutrition	5B50-5B71	Approved	[7]

Drug(s) Targeting Glutamate receptor ionotropic NMDA 2A (NMDAR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[31]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[32]
Spermine	DMD4BFY	N. A.	N. A.	Terminated	[33]
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[34]
L-698544	DMLRBN1	Alzheimer disease	8A20	Terminated	[35]
Dizocilpine	DMMGYXR	Cerebrovascular ischaemia	8B1Z	Terminated	[36]
RPR-104632	DM9L50N	N. A.	N. A.	Terminated	[37]
L-698532	DMO9HM7	Neurological disorder	6B60	Terminated	[38]
L-695902	DMT1DNS	N. A.	N. A.	Terminated	[35]
L-701324	DMAIJSX	Cerebrovascular ischaemia	8B1Z	Terminated	[38]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor ionotropic NMDA 2A (NMDAR2A)	TTKJEMQ	NMDE1_HUMAN	Antagonist	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium- and chloride-dependent glycine transporter 1 (SLC6A9)	DT2CFQ5	SC6A9_HUMAN	Substrate	[4]
Sodium- and chloride-dependent glycine transporter 2 (SLC6A5)	DTE8R17	SC6A5_HUMAN	Substrate	[5]
Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)	DTBPTJF	S6A12_HUMAN	Substrate	[6]
L-type amino acid transporter 2 (SLC7A8)	DTJF3DX	LAT2_HUMAN	Substrate	[7]
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)	DTW7AE3	AAAT_HUMAN	Substrate	[8]
Proton-coupled amino acid transporter 1 (SLC36A1)	DT48WEM	S36A1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Bile acid-CoA thioesterase (BAAT)	DERA3OF	BAAT_HUMAN	Substrate	[10]
Delta-aminolevulinate synthase 2 (ALAS2)	DE437BY	HEM0_HUMAN	Substrate	[11]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 727).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016784.
• [3] Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78.
• [4] Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans. Hum Genet. 2016 Nov;135(11):1263-1268.
• [5] Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease. J Biol Chem. 2012 Aug 17;287(34):28975-85.
• [6] Interpreting metabolomic profiles using unbiased pathway models. PLoS Comput Biol. 2010 Feb 26;6(2):e1000692.
• [7] The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
• [8] Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1046-53.
• [9] Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci. 2008 Sep 2;35(1-2):86-95.
• [10] Bile acid coenzyme A: amino acid N-acyltransferase in the amino acid conjugation of bile acids. Methods Enzymol. 2005;400:374-94.
• [11] Molecular expression and characterization of erythroid-specific 5-aminolevulinate synthase gain-of-function mutations causing X-linked protoporphyria. Mol Med. 2013 Mar 5;19:18-25.
• [12] Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem. 1994 Jul 29;269(30):19375-9.
• [13] Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
• [14] A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70.
• [15] High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5.
• [16] Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47.
• [17] Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.
• [18] Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506.
• [19] D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
• [20] PAT1 (SLC36A1) shows nuclear localization and affects growth of smooth muscle cells from rats. Am J Physiol Endocrinol Metab. 2014 Jan 1;306(1):E65-74.
• [21] Indirect regulation of the intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1). J Cell Physiol. 2005 Aug;204(2):604-13.
• [22] Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol. 2010 Mar;159(6):1339-53.
• [23] Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol. 2009 Aug;157(8):1380-9.
• [24] Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. Pharm Res. 2012 Apr;29(4):1134-42.
• [25] The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.22.3.1)
• [26] Deletion of the betaine-GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice. Epilepsy Res. 2011 Jun;95(1-2):70-81.
• [27] SLC6A2 Gene (Protein Coding).
• [28] SLC6 transporters: structure, function, regulation, disease association and therapeutics. Mol Aspects Med. 2013 Apr-Jun;34(2-3):197-219.
• [29] Glycine is taken up through GLYT1 and GLYT2 transporters into mouse spinal cord axon terminals and causes vesicular and carrier-mediated release of its proposed co-transmitter GABA. J Neurochem. 2001 Mar;76(6):1823-32.
• [30] Quantifying the relative contributions of different solute carriers to aggregate substrate transport. Sci Rep. 2017 Jan 16;7:40628.
• [31] Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
• [32] 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
• [33] Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
• [35] Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
• [36] Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
• [37] Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
• [38] Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.